Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for XOMA Corporation (XOMA : NSDQ)

• Company Description    XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1? with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California. Number of Employees: 12

• Price / Volume Information    Yesterday's Closing Price: $17.21 Daily Weekly Monthly 20 Day Moving Average: 37,748 shares Shares Outstanding: 11.42 (millions) Market Capitalization: $196.55 (millions) Beta: 1.09 52 Week High: $39.02 52 Week Low: $16.96 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -28.91% -22.40% 12 Week -14.51% -7.60% Year To Date -17.46% -2.23%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2200 POWELL STREET SUITE 310 - EMERYVILLE,CA 94608 USA ph: 510-204-7200 fax: 510-649-7571 investorrelations@xoma.com http://www.xoma.com

• General Corporate Information    Officers James R. Neal - Chief Executive Officer and Chairman of the Board Thomas Burns - Senior Vice President; Finance and Chief Financial W. Denman Van Ness - Director Joseph M. Limber - Director Jack L. Wyszomierski - Director Peer Information XOMA Corporation (CORR.) XOMA Corporation (RSPI) XOMA Corporation (CGXP) XOMA Corporation (BGEN) XOMA Corporation (GTBP) XOMA Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 98419J206 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 11.42 Most Recent Split Date: 10.00 (0.05:1) Beta: 1.09 Market Capitalization: $196.55 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.10 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.33 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 32.47 PEG Ratio: - Price Ratios Price/Book: 1.40 Price/Cash Flow: 23.81 Price / Sales: 4.81 EPS Growth vs. Year Ago Period: 54.29% vs. Previous Quarter: -119.16% Sales Growth vs. Year Ago Period: 728.53% vs. Previous Quarter: -91.36% ROE 03/31/22 - 8.77 12/31/21 - 4.93 09/30/21 - 1.39 ROA 03/31/22 - 7.56 12/31/21 - 4.02 09/30/21 - 1.08 Current Ratio 03/31/22 - 11.36 12/31/21 - 7.48 09/30/21 - 11.51 Quick Ratio 03/31/22 - 11.36 12/31/21 - 7.48 09/30/21 - 11.50 Operating Margin 03/31/22 - 27.35 12/31/21 - 14.57 09/30/21 - 4.63 Net Margin 03/31/22 - 27.35 12/31/21 - 14.57 09/30/21 - 4.63 Pre-Tax Margin 03/31/22 - 51.31 12/31/21 - 41.64 09/30/21 - 29.01 Book Value 03/31/22 - 12.27 12/31/21 - 12.54 09/30/21 - 9.86 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©